CGRP Migraine Drugs Also Reduce Oxidative Stress Biomarkers in Treatment-Resistant Patients | Research

The takeaway

CGRP inhibitors (erenumab, fremanezumab, galcanezumab) reduced oxidative stress biomarkers alongside dramatic migraine improvement in treatment-resistant patients, with 70% achieving ≥50% headache reduction by month 3.

70% responder rate at 3 months
In treatment-resistant migraine patients with medication overuse headache — among the most difficult cases to treat

What the researchers found

CGRP inhibitors reduced AOPP (oxidative stress biomarker) over 6 months alongside 70% responder rates and significant improvements in disability, allodynia, fatigue, anxiety, and sleep quality in resistant migraineurs.

Why it matters

Treatment-resistant migraine patients represent the greatest clinical challenge. Showing that CGRP inhibitors not only reduce headaches but also improve oxidative stress and multiple comorbidities supports their use as transformative therapies for the most difficult cases.

The numbers in context

70% 50% responders at 3 mo; ~25% 75% responders at 1 mo; AOPP decreased at 6 mo; allodynia moderate→mild; MIDAS improved

How the study worked

Real-world prospective study in tertiary headache center patients with high-frequency resistant migraine and medication overuse headache. Three CGRP mAbs used (erenumab, fremanezumab, galcanezumab). Oxidative stress biomarkers, headache frequency, MIDAS, allodynia, and comorbidity measures assessed at 3 and 6 months.

Who was studied

Treatment-resistant migraine patients with medication overuse at a tertiary headache center

What this study cannot tell us

No control group. Real-world study without randomization or blinding. Small sample size implied. Oxidative stress is a biomarker with uncertain clinical significance in migraine.

How to read the evidence

Prospective real-world study without control group. Provides practice-relevant effectiveness data with novel biomarker findings.

When this study was published

Published in 2021, from early real-world clinical experience with CGRP inhibitors in the most challenging migraine patients.

The bigger picture

The finding that CGRP inhibitors reduce oxidative stress adds a new dimension to understanding how these drugs work. Oxidative stress may be both a consequence and driver of chronic migraine, and its reduction could help explain the broad clinical improvements seen beyond simple headache frequency reduction.

Questions still open

Is oxidative stress reduction a mechanism or consequence of migraine improvement?
Could AOPP serve as a predictive biomarker for CGRP inhibitor response?
Do the three CGRP antibodies differ in their oxidative stress-reducing effects?

Common questions

Do CGRP drugs work for the hardest-to-treat migraines?

Yes. In this study of patients with treatment-resistant migraine and medication overuse headache, 70% achieved at least 50% headache reduction within 3 months. Many also experienced improvements in sleep, anxiety, fatigue, and pain sensitivity.

What does oxidative stress have to do with migraines?

Oxidative stress — damage caused by unstable molecules called free radicals — may play a role in chronic migraine. This study found that CGRP inhibitors reduced a biomarker of oxidative stress (AOPP), suggesting these drugs may address an underlying biological process beyond just blocking pain signals.

Read the original research

CGRP Inhibitors and Oxidative Stress Biomarkers in Resistant Migraine: A Real-Life Study with Erenumab, Fremanezumab, and Galcanezumab.

Journal of clinical medicine, 10(19)

View on PubMed ↗Publisher’s paper ↗

Citation

De Luca, Ciro; Baldacci, Filippo; Mazzucchi, Sonia; Lombardo, Irene; Curto, Letizia; Ulivi, Martina; Chico, Lucia; Papa, Michele; Siciliano, Gabriele; Gori, Sara. (2021). CGRP Inhibitors and Oxidative Stress Biomarkers in Resistant Migraine: A Real-Life Study with Erenumab, Fremanezumab, and Galcanezumab.. Journal of clinical medicine, 10(19). https://doi.org/10.3390/jcm10194586